Abstract
We sought to determine whether a low-dose combination of a bile acid–binding resin (colestipol) with an hydroxymethylglutaryl CoA reductase inhibitor (pravastatin) would result in improved acceptability, compliance, and effectiveness in lipid-lowering compared with conventional therapy with a higher dose of a bile acid–binding resin only, with fewer side effects. We performed a randomized, crossover open-label clinical trial with two 18-wk medication regimens separated by an 8-wk washout period in 36 children and adolescents with familial hypercholesterolemia or familial combined hyperlipidemia. The regimens included colestipol 10 g/d (10 pills) versus a combination of colestipol 5 g/d with pravastatin 10 mg/d (six pills). All patients were maintained on a fat-reduced diet. Acceptability was better with the combination regimen. Mean compliance was similar and suboptimal (approximately 60%) with all medication components. Mean relative LDL cholesterol lowering was significantly better with the combination regimen (−17 ± 16%versus −10 ± 13%;p = 0.045), although insufficient to achieve recommended target values in the majority of patients on either regimen. Both regimens were equally free of adverse effects, with no important effect on chemistry or hematologic values. Patient-reported adverse effects were more common with the conventional-dose colestipol-only regimen. Compliance with medication regimens using the bile acid–binding resins is suboptimal, although combination with a low dose of a statin may result in better lipid lowering.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- HMG:
-
hydroxymethylglutaryl
- NCEP:
-
National Cholesterol Education Program
References
Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L 1996 Efficacy safety of cholestyramine therapy in peripubertal prepubertal children with familial hypercholesterolemia. J Pediatr 129: 42–49
McCrindle BW, O'Neill MB, Cullen-Dean G, Helden E 1997 Acceptability compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J Pediatr 130: 266–273
Tonstad S, Ose L 1996 Colestipol tablets in adolescents with familial hypercholesterolaemia. Acta Paediatr 85: 1080–1082
Ducobu J, Brasseur D, Chaudron JM, Deslypere JP, Harvengt C, Muls E, Thomson M 1992 Simvastatin use in children “letter”. Lancet 339: 1488
Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer BE, van den Ende A, Buller HR, Bakker HD 1996 Short-term efficacy safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 39: 867–871
Lambert M, Lupien PJ, Gagne C, Levy E, Blaichman S, Langlois S, Hayden M, Rose V, Clarke JT, Wolfe BM, Clarson C, Parsons H, Stephure DK, Potvin D, Lambert J 1996 Treatment of familial hypercholesterolemia in children adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 97: 619–628
Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouris CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ 1999 Efficacy safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 281: 137–144
American Academy of Pediatrics 1992 National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children Adolescents. Pediatrics 89: 525–584
Cole TJ, Freeman JV, Preece MA 1996 Body mass index reference curves for the UK, 1990. Arch Dis Child 73: 25–29
McGill HC, McMahan CA 1998 Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol 82: 30T–36T
Berenson GS, Wattigney WA, Tracy RE, Newman WP III, Srinivasan SR, Webber LS, Dalferes ER Jr, Strong JP 1992 Atherosclerosis of the aorta coronary arteries cardiovascular risk factors in persons aged 6 to 30 years studied at necropsy (The Bogalusa Heart Study). Am J Cardiol 70: 851–858
Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA 1998 Association between multiple cardiovascular risk factors atherosclerosis in children young adults. The Bogalusa Heart Study. N Engl J Med 338: 1650–1656
Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP, Herderick EE, Cornhill JF 1999 Prevalence extent of atherosclerosis in adolescents young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 281: 727–735
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE 1992 Non-invasive detection of endothelial dysfunction in children adults at risk of atherosclerosis. Lancet 340: 1111–1115
Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE 1994 Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia is related to the lipoprotein(a) level. J Clin Invest 93: 50–55
Aggoun Y, Bonnet D, Sidi D, Girardet JP, Brucker E, Polak M, Safar ME, Levy BI 2000 Arterial mechanical changes in children with familial hyperlipidemia. Arterioscler Thromb Vasc Biol 20: 2070–2075
Mahoney LT, Burns TL, Stanford W, Thompson BH, Witt JD, Rost CA, Lauer RM 1996 Coronary risk factors measured in childhood young adult life are associated with coronary artery calcification in young adults: the Muscatine Study. J Am Coll Cardiol 27: 277–284
Davis PH, Dawson JD, Mahoney LT, Lauer RM 1999 Increased carotid intimal-medial thickness coronary calcification are related in young middle-aged adults. The Muscatine Study. Circulation 100: 838–842
Pauciullo P, Iannuzzi A, Sartorio R, Irace C, Covetti G, Di Costanzo A, Rubba P 1994 Increased intima-media thickness of the common carotid artery in hypercholesterolemic children. Arterioscler Thromb 14: 1075–1079
Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D, Bonaa KH 1996 Risk factors related to carotid intima-media thickness plaque in children with familial hypercholesterolemia control subjects. Arterioscler Thromb Vasc Biol 16: 984–991
Ose L, Tonstad S 1995 The detection management of dyslipidaemia in children adolescents. Acta Paediatr 84: 1213–1215
Tonstad S 2000 Role of lipid-lowering pharmacotherapy in children. Paediatr Drugs 2: 11–22
Kimm SY, Payne GH, Stylianou MP, Waclawiw MA, Lichtenstein C 1998 National trends in the management of cardiovascular disease risk factors in children: second NHLBI survey of primary care physicians. Pediatrics 102: E50
Wheeler KA, West RJ, Lloyd JK, Barley J 1985 Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 60: 34–37
Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW 1993 Niacin treatment of hypercholesterolemia in children. Pediatrics 92: 78–82
Hennermann JB, Herwig J, Marz W, Asskali F, Bohles HJ 1998 Lipid lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy. Eur J Pediatr 157: 912–918
Duplaga BA 1999 Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors. Ann Pharmacother 33: 1224–1227
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McCrindle, B., Helden, E., Cullen-Dean, G. et al. A Randomized Crossover Trial of Combination Pharmacologic Therapy in Children with Familial Hyperlipidemia. Pediatr Res 51, 715–721 (2002). https://doi.org/10.1203/00006450-200206000-00009
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-200206000-00009
This article is cited by
-
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia
Current Atherosclerosis Reports (2022)
-
Dyslipidemia and cardiovascular health in childhood nephrotic syndrome
Pediatric Nephrology (2020)
-
Chapter 4: Pharmacological cholesterol-lowering treatment in children
Kidney International Supplements (2013)
-
References
Kidney International Supplements (2013)
-
Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: A review
Journal of Endocrinological Investigation (2007)
